In addition to disrupting the balance between tumor suppressors and oncogenes, Pin1 has been identified as a key player in cancer therapeutic resistance, notably in breast, pancreatic, and hepatocellular carcinoma (HCC) (34–36), which could potentially be treated based on therapy using a combination of Pin1 inhibitors and chemotherapeutic agents (37). The gene discussed is PIN1; the disease is neoplasm.